Alpharma Preps For NSAID Patch Launch One Year After Approval
Executive Summary
Alpharma is gearing up for the launch of the first non-steroidal anti-inflammatory patch, Flector Patch, during the second week of January, one year after FDA approved the drug. Flector Patch is approved for the topical treatment of acute pain due to minor strains, sprains and contusions
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.